
2005年9月-2009年7月 山东大学药学院, 学士
2009年9月-2014年7月 中国科学院上海药物研究所药物设计专业,博士
2015年2月-2020年7月 The Johns Hopkins University School of Medicine,博士后
2020年8月至今 中国科学院广州生物医药与健康研究院,研究员
2025年 广州健康院2025年度抢占科技制高点优秀奖
2023年 中国科学院率先行动高层次人才引进计划
2022年 广东省青年拔尖人才
2019年 美国癌症研究协会(AACR)Scholar in Training Award
1. Kong X#, Chen J#, Xie W#, Brown S, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann R, Tao Y, Yen R, Topper MJ, Easwaran H, Rothbart SB*, Xia L*, Baylin SB*, Defining UHRF1 Domains That Support Maintenance of Human Colon Cancer DNA Methylation and Oncogenic Properties, Cancer Cell. 2019;35(4):633-648
2. Tang S#,*, Zong L#, Ma S#, Shang Y#, Wei J#, Liu J, Cui Y, Guo H, Zou K, Wang K, Li H, Ye F, Huang J, Luo C, Li Z*, Baylin SB*, Kong X*, Structure-Guided Design of 7‑Azaindole DNMT1 Inhibitors Active Against Hypomethylating Agent‑Resistant Acute Myeloid Leukemia, Proc Natl Acad Sci U S A. 2026;123(15):e2532472123
3. Xia C, Cui Y, Wang J, Bai W, Wang D, Chen Y, Guo H, Zong L, Qin B, Cai X, Wang J, Huang J, Rothbart SB, Guo Z*, Baylin SB*, Kong X*, Reduced Maintenance DNA Methylation Thresholds Enable Sensitive Reporter Assays for UHRF1 and DNMT1 Inhibition, Adv Sci. 2026:e19080 (doi: 10.1002/advs.202519080)
4. Wei Y#, Gao Y#, Li R, Chen Y, Bai W, Zhao P, Hu J, Li L, Wang X, Yin G, Dang Y*, Kong X*, Guo Z*, High-Throughput Ligand Discovery in Living Cells Using the Cellular Protein Stability Enhancement Assay, Acta Pharm Sin B. 2026; In press (doi.org/10.1016/j.apsb.2026.02.008)
5. Shen Y#, Wei J#, Tang S#, Wu D, Zong L, Ma S, Xiong Q, Gong R, Xu S, Peng C, Feng Q, Liu S, Liu Q, Ye Y, Zhao Q, Luo C, Huang P, Li Z*, Kong X*, Lan X*, Discovery of a Novel DNMT1 Inhibitor with Improved Efficacy in Treating β-Thalassemia, Adv Sci. 2026;13(11):e13469.
6. Li Y#, Wang J#, Zhou L#, Gu W#, Qin L, Peng D, Li S, Zheng D, Wu Q, Long Y, Yao Y, Lin S, Sun M, Zhang X, Wang J, Liu P, Kong X*, Li P*, DNMT1 inhibition reprograms T cells to NK-like cells with potent antitumor activity, Sci Immunol. 2025;10(105): eadm8251.
7. Bai W#, Xu J#, Gu W#, Wang D#, Cui Y#, Rong W, Du X, Li X, Xia C, Gan Q, He G, Guo H, Deng J, Wu Y, Yen R, Yegnasubramanian S, Rothbart S, Luo C, Wu L, Liu J*, Baylin S*, Kong X*, Defining Ortholog-specific UHRF1 Inhibition by STELLA for Cancer Therapy, Nat Commun. 2025;16(1):474.
8. Cai M#, Xiao Y#, Zheng J#, Shi J, Wu J, Kong X*, Liang Z*, Mapping Context-Aware Phosphosite Regulation of Protein–Protein Interactions Using Deep Learning and Pan-Cancer Proteomics, J Chem Inf Model. 2025;65(20):11255-11271
9. Chang Y#, Guo H#, Li X#, Zong L, Wei J, Li Z, Luo C, Yang X, Fang H, Kong X*, Hou X*, Development of a First-in-Class DNMT1/HDAC Inhibitor with Improved Therapeutic Potential and Potentiated Antitumor Immunity, J Med Chem. 2024;67(18):16480-16504



